NA
NDRA icon

NewEdge Advisors’s ENDRA Life Sciences NDRA Stock Holding History

NewEdge Advisors’s Portfolio NDRA Stock Details NDRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed -$113 – 3978
2024
Q3 		$113 Buy
20
+3
+18% +$232 ﹤0.01% 3714
2024
Q2 		$2.91K Sell
17
-1
-6% -$431 ﹤0.01% 3256
2024
Q1 		$18K Hold
18
– – ﹤0.01% 2665
2023
Q4 		$66.3K Hold
18
– – ﹤0.01% 2114
2023
Q3 		$35.6K Hold
18
– – ﹤0.01% 2198
2023
Q2 		$45.2K Sell
18
-1
-5% -$2.82K ﹤0.01% 2113
2023
Q1 		$74.6K Hold
19
– – ﹤0.01% 1848
2022
Q4 		$134 Hold
19
– – ﹤0.01% 3341
2022
Q3 		$201K Hold
19
– – ﹤0.01% 1359
2022
Q2 		$153K Hold
19
– – ﹤0.01% 1431
2022
Q1 		$258K Hold
19
– – ﹤0.01% 982
2021
Q4 		$462K Sell
19
-1
-5% -$42.5K 0.01% 1116
2021
Q3 		$1.22M Hold
20
– – 0.03% 456
2021
Q2 		$1.54M Buy
+20
New +$1.57M 0.04% 371

Other funds holding NDRA

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

NewEdge Advisors's NDRA Position: Q4 2024 in Review

NewEdge Advisors sold out of ENDRA Life Sciences (NDRA) in Q4 2024, closing a stake of 20 shares — an estimated $113 sold.

NewEdge Advisors first reported a position in NDRA in Q2 2021 and held it in 14 quarters. The position peaked at $1.54M in Q2 2021. 4 funds tracked by Wall St. Rank hold NDRA as of Q4 2024.

  • NewEdge Advisors reported no remaining ENDRA Life Sciences position as of Q4 2024 after selling out during the quarter.
  • NewEdge Advisors sold 20 ENDRA Life Sciences shares in Q4 2024, an estimated $113.
  • NewEdge Advisors first reported a position in ENDRA Life Sciences in Q2 2021 and held it in 14 quarters.
  • NewEdge Advisors's ENDRA Life Sciences position peaked at $1.54M in Q2 2021.
  • 4 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q4 2024.

Based on NewEdge Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.